#Sweden #Brand Identity #Lund #Clinical Research #TFS HealthScience

TFS HealthScience Unveils New Global Brand Identity

On October 5, 2026, TFS HealthScience, a global clinical research organization (CRO) based in Lund, Sweden, launched an exciting new brand identity along with the slogan, "Securing the Path from Science to Life." This initiative aims to clearly define how TFS collaborates with sponsors across the biotechnology, pharmaceutical, and medtech sectors in over 40 countries. The foundation of this brand identity is built upon four key pillars: radical honesty, scientific urgency, therapeutic specialization, and team continuity.

Markus Granlund, CEO of TFS HealthScience, expressed that the new brand accurately reflects the organization's essence and direction. He stated, "We secure the path from science to real life, thanks to a great team that strives for excellence every day."

What the New Brand Represents

The refreshed identity connects each study with the company's mission of applying a human-centric approach to clinical development. This is essential for ensuring that promising scientific advancements reach the patients who need them most. TFS originated in Lund with a commitment to conducting clinical research that provides sponsors with precise data insights, acts with urgency, and maintains continuity with the same experts from the first patient inclusion to database locking.

Key Commitments to Sponsors

TFS’s new identity encapsulates four vital commitments that sponsors can rightfully expect:

1. Radical Honesty: TFS teams are committed to communicating to sponsors exactly what the data indicates, bringing to light relevant aspects in advance to maintain transparency and trust.

2. Scientific Urgency: Authority for decision-making is directly vested in the leaders of each therapeutic area, enabling rapid responses for sponsors without the delays of lengthy escalation chains.

3. Therapeutic Specialization: Focusing on five key therapeutic areas—dermatology, internal medicine, neuroscience, oncology, and ophthalmology—TFS ensures that clinical leads are well-acquainted with the specific indications before embarking on any project.

4. Continuity of Teams: An impressive 88% of TFS’s teams remain with a project throughout the study, which is 8 percentage points higher than the industry average. The professionals who initiate a clinical trial remain involved until the database closure, enhancing study consistency and quality.

Flexible Collaboration Models

TFS collaborates with sponsors through a variety of engagement models, including comprehensive service provision and team integration, tailored to meet the unique needs of each sponsor. This flexibility empowers clients to manage their internal processes effectively while leveraging TFS’s expertise where needed.

About TFS HealthScience

Founded in 1996 in Lund, Sweden, TFS HealthScience is a global clinical research organization that works with biotech, pharmaceutical, and medtech sponsors to ensure that scientific discoveries translate into real-life applications. The company operates in over 40 countries and focuses on five therapeutic areas: dermatology, internal medicine, neuroscience, oncology, and ophthalmology. For additional information, please visit tfscro.com.